ClinicalTrials.gg
CompletedNCT01038661TFINEUpdated Feb 28, 2014

Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy

A Phase 3 interventional study of Docetaxel and Cisplatin in Lung Neoplasms, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing docetaxel in Lung Neoplasms — 1 open to participants now, 3 under way, 1 of them phase 3. Docetaxel · Lung Neoplasms.

Enrollment
5th of 90
375 · median 46
Started
2009
with 5 others
Phase 3
11 of 100
none open now
Registered
75th of 100
by date
Lead sponsor
5 of 100
Sanofi

Among the 100 studies testing docetaxel in Lung Neoplasms, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2009, is one of 11 in phase 3, and was the 75th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

1 of the 100 studies testing docetaxel in Lung Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing docetaxel in Lung Neoplasms, or all of them as a file.
02

Study summary

The Primary Objective is to evaluate the progression-free survival (PFS).

The secondary objectives are:

  • To compare the disease control rates of different doses of Docetaxel+Cisplatin as first-line treatment according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria;
  • To evaluate the overall response rate (ORR);
  • To evaluate the time to disease progression (TTP);
  • To evaluate the overall survival (OS);
  • To evaluate the toxicity.
Read the detailed description

The study consists in:

  • A first line treatment phase: participants receive 4 cycles of chemotherapy (each cycle contains 3 weeks) with either docetaxel (75 mg/m2) plus cisplatin (75 mg/m2) or docetaxel (60 mg/m2) plus cisplatin (75 mg/m2) ,
  • A maintenance treatment phase: participants with disease control (complete response [CR], partial response [PR] or stable disease [SD]) after the initial treatment receive up to 6 cycles of chemotherapy with docetaxel (60 mg/m2) or best supportive care (BSC).
  • A follow-up period from the end of study treatment until participant death or end of study.
03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis of advanced non-small-cell lung cancer (NSCLC)
  • Based on International Association for the Study of Lung Cancer (IASLC) 2009 new Tumor-Node- (TNM) stage criteria of lung cancer, local advanced stage IIIB (not applicable for radical radiation therapy) disease or metastatic stage IV disease or recurrent disease
  • At least one evaluable tumor lesion based on criteria (>= 20 mm with conventional techniques or >= 10 mm with spiral Computed Tomography scan)
  • performance status (ECOG PS) 0/1
  • Adequate bone marrow reserve

    • >= 2.0×10\^9/L
    • >= 100×10\^9/L
    • >= 9.0 g/dL
  • Adequate hepatic function

    • total \<= Upper Normal Limit (UNL)
    • Aspartate Amino Transferase (), Alanine Amino Transferase (ALT) \<= 2.5 UNL
    • alkaline phosphatase (ALP) \<= 5 UNL
  • Adequate renal function (serum creatinine \<= UNL or >= 60 mL/min)
  • No prior chemotherapy was allowed or only (neo) chemotherapy ended more than 6 months before treatment (patients should not have been heavily pre-treated, the maximum cumulative dose of cisplatin allowed is 350 mg/m²)
  • Prior surgery was permitted only if the operation performed more than 4 weeks ago and the patient was completely recovery
  • either terminated or attenuated by the use of an approved method
  • Inform consent signed

Exclusion criteria

Exclusion criteria:

  • Other tumour type than advanced / NSCLC in recent 5 years (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin).
  • Presence of symptomatic central nervous system metastases
  • Inadequate liver function

    • total > 1 UNL
    • and/or AST>1.5 UNL associated with alkaline phosphatase > 2.5 UNL
    • inadequate renal function (creatinine > 1.0 times UNL and in case of limit value, \< 60 mL/min)
  • Prior radiation therapy, or surgery operation within 4 weeks
  • Prior use of taxoids
  • Active infection, or serious concomitant systemic disorder incompatible with the study
  • but unwilling to use of an approved method
  • Receive treatment from other clinical trials during this study treatment
  • History of to any of study medication
  • Other serious concomitant abnormal or illness

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²

    Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles

    Drug: Docetaxel · Drug: Cisplatin

  • Experimental
    First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²

    Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles

    Drug: Docetaxel · Drug: Cisplatin

  • Experimental
    Maintenance treatment: docetaxel (60 mg/m2)

    Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles

    Drug: Docetaxel

  • Active comparator
    Maintenance treatment: best supportive care (BSC)

    BSC until progressive disease

    Other: Best supportive care (BSC)

Interventions

  • Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-hour IV

    Also known as: Taxotere®

  • Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-3-hour IV

  • OtherBest supportive care (BSC)

    Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) during the maintenance treatment phase

    Time frame: From 2nd randomization to progression or death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period)

Secondary outcomes

  1. Disease control rate (DCR) during the first line treatment phase

    Time frame: Every 2 cycles (6 weeks)

  2. Overall response rate (ORR) during the first line treatment phase

    Time frame: Every 2 cycles (6 weeks)

  3. Time to disease progression (TTP) during the maintenance treatment phase

    Time frame: From 2nd randomization up to disease progression (every 2 cycles (6 weeks))

  4. Overall survival (OS)

    Time frame: From 1st randomization to death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period)

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Shanghai, China
08

References and documents

Publications

  • Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, Chen G, Liu X, Yang J, Zhang L, Chen J, Huang M, Tao M, Cheng G, Huang C, Zhou C, Zhang W, Zhao H, Sun Y. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med. 2021 Feb;9(4):338. doi: 10.21037/atm-20-8078. PubMed 33708965 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2009
First posted
Dec 24, 2009
Start
Nov 2009
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Feb 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01038661
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 24, 2009
Start date
Nov 2009
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Feb 28, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin

Start the discussion